X4 Pharmaceuticals to Showcase Innovations at Notable Conference
BOSTON – X4 Pharmaceuticals (NASDAQ: XFOR), a company dedicated to enhancing the lives of individuals with rare immune system diseases, has announced its participation in the prestigious Annual Piper Sandler Healthcare Conference. This significant event will be held from December 3 to 5, creating a vital opportunity for the company to connect with investors and industry leaders.
Key Details of the Conference Participation
At this year's conference, X4 Pharmaceuticals will engage healthcare professionals, investors, and analysts in a fireside chat format scheduled for 11:00 AM ET on December 3. The venue, Lotte New York Palace, is set to host influential figures from across the healthcare sector, making it an essential gathering for those interested in advancements in medical therapies.
Webcast Accessibility
For those unable to attend in person, a live webcast will allow remote participation. Attendees can access the webcast through the X4 Pharmaceuticals investor section on their website. This feature ensures that all interested parties can stay informed about the latest updates from the company as they share insights into their innovative therapies.
Networking Opportunities
X4 Pharmaceuticals leadership will offer exclusive one-on-one meetings during the conference. This option allows interested investors to discuss the company’s trajectory and future developments in more detail. Interested parties are encouraged to reach out to their Piper Sandler representatives to arrange these meetings.
About X4 Pharmaceuticals
X4 Pharmaceuticals is on a mission to improve the lives of patients suffering from rare diseases linked to the immune system. The company has made significant strides in the development of mavorixafor, capturing attention with its U.S. approval under the name XOLREMDI (mavorixafor) capsules. This groundbreaking drug addresses severe unmet medical needs and highlights X4’s commitment to advancing healthcare.
Continued Innovation in Treatment Options
In addition to the current approval, X4 Pharmaceuticals is exploring further applications of mavorixafor for other medical indications, demonstrating their innovative approach in medicine. Their ongoing research activities emphasize the company’s dedication to finding solutions for patients facing immune-related challenges.
Company Headquarters and Contact Information
X4 Pharmaceuticals is headquartered in Boston, with a research center of excellence in Vienna, Austria. The company's strategic location allows it to tap into global research talents and market opportunities.
Company Contact:
José Juves
Head of Corporate & Patient Affairs
jose.juves@x4pharma.com
Investor Contact:
Daniel Ferry
Managing Director, LifeSci Advisors
daniel@lifesciadvisors.com
(617) 430-7576
Frequently Asked Questions
What is the purpose of the Piper Sandler Healthcare Conference?
The Piper Sandler Healthcare Conference serves as a platform for companies to present their innovations and future plans to investors and stakeholders within the healthcare industry.
When is X4 Pharmaceuticals presenting at the conference?
X4 Pharmaceuticals will present at the conference on December 3 at 11:00 AM ET in a fireside chat format.
How can I access the conference webcast?
The webcast can be accessed through the investors section on the X4 Pharmaceuticals website, providing remote participants access to the live event.
What does X4 Pharmaceuticals focus on?
X4 Pharmaceuticals focuses on developing therapies for rare diseases of the immune system, aiming to fulfill significant unmet medical needs.
Who can I contact for investor inquiries?
For investor inquiries, contact Daniel Ferry, Managing Director at LifeSci Advisors, via email at daniel@lifesciadvisors.com.
